MCID: HST010
MIFTS: 53

Histiocytosis

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Histiocytosis

MalaCards integrated aliases for Histiocytosis:

Name: Histiocytosis 12 54 43 15 71
Hand Schuller Christian Disease 12
Hand-Schüller-Christian Disease 74
Histiocytosis, Langerhans-Cell 71
Chronic Histiocytosis X 12
Histiocytic Syndrome 71

Classifications:



External Ids:

Disease Ontology 12 DOID:3405
MeSH 43 D015614
NCIt 49 C3106
SNOMED-CT 67 60657004 65396000
UMLS 71 C0019618 C0019621 C0398597

Summaries for Histiocytosis

Disease Ontology : 12 A lymphatic system disease that is characterized by an excessive number of histiocytes.

MalaCards based summary : Histiocytosis, also known as hand schuller christian disease, is related to alk+ histiocytosis and malignant histiocytosis. An important gene associated with Histiocytosis is SLC29A3 (Solute Carrier Family 29 Member 3), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Trametinib and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and lymph node, and related phenotypes are osteolysis and proptosis

Wikipedia : 74 Hand-Schuller-Christian disease is associated with multifocal Langerhans cell... more...

Related Diseases for Histiocytosis

Diseases in the Histiocytosis family:

Malignant Histiocytosis

Diseases related to Histiocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 984)
# Related Disease Score Top Affiliating Genes
1 alk+ histiocytosis 34.3 CD207 CD1A
2 malignant histiocytosis 34.2 TNFRSF8 SERPINA3 CD1A
3 non-langerhans-cell histiocytosis 33.8 SERPINA3 CD207 CD1C CD1A CD163
4 juvenile xanthogranuloma 33.1 SERPINA3 S100B CD1A BRAF
5 erdheim-chester disease 32.9 SERPINA3 NRAS CD1C CD1A CCR6 BRAF
6 rosai-dorfman disease 32.7 STAB1 SLC29A3 S100B MAP2K1 CD163 BRAF
7 dendritic cell tumor 32.5 S100B PTPRC CD207 CD1A
8 langerhans cell sarcoma 32.5 TNFRSF8 CD207 CD1C CD1A
9 reticulohistiocytic granuloma 32.3 SERPINA3 CD207 CD1C CD1A CD163
10 langerhans cell histiocytosis 31.5 U2AF1 S100B PTPRC NRAS MAP2K1 ITGAX
11 histiocytic sarcoma 30.8 CD163 BRAF
12 seborrheic dermatitis 30.8 CD207 CD1C CD1A
13 marginal zone b-cell lymphoma 30.4 U2AF1 TNFRSF8 CCR6
14 meningioma, familial 30.3 SERPINA3 PECAM1 CD1C CD1A
15 histiocytoma 30.3 SERPINA3 PTPRC PECAM1 CD1A CD163
16 plasma cell neoplasm 30.3 TNFRSF8 SERPINA3 PTPRC
17 lethal midline granuloma 30.3 TNFRSF8 SERPINA3
18 hodgkin's lymphoma, lymphocytic-histiocytic predominance 30.2 TNFRSF8 PTPRC
19 sarcoidosis 1 30.2 SERPINA3 PTPRC IL1RN CCR6
20 polyclonal hypergammaglobulinemia 30.2 SLC29A3 SERPINA3 CD1C CD1A
21 malignant fibroxanthoma 30.1 TNFRSF8 SERPINA3 PTPRC
22 hairy cell leukemia 30.1 U2AF1 MAP2K1 ITGAX BRAF
23 granuloma annulare 30.1 CD1C CD1A CD163
24 rhinoscleroma 30.0 CD1C CD1A
25 fibrous histiocytoma 30.0 SERPINA3 S100B PECAM1 CD163
26 reticulosarcoma 30.0 TNFRSF8 SERPINA3 PTPRC
27 skin sarcoidosis 30.0 CD1C CD1A
28 lymph node disease 29.9 SERPINA3 PTPRC ITGAX CCR6
29 mycosis fungoides 29.9 TNFRSF8 CD1C CD1A CCR6
30 orbital cancer 29.9 CD1C CD1A
31 bone lymphoma 29.9 TNFRSF8 PTPRC
32 amelanotic melanoma 29.8 SERPINA3 S100B BRAF
33 interdigitating dendritic cell sarcoma 29.8 SERPINA3 CD1C CD1A
34 sarcoma 29.8 S100B PTPRC NRAS MAP2K1 BRAF ARAF
35 myeloma, multiple 29.8 U2AF1 TNFRSF8 PTPRC NRAS CCR6 BRAF
36 spongiotic dermatitis 29.8 CD1C CD1A CCR6
37 hodgkin's lymphoma, mixed cellularity 29.7 TNFRSF8 PTPRC
38 giant cell tumor 29.6 SERPINA3 S100B PTPRC
39 reticulum cell sarcoma 29.6 TNFRSF8 PTPRC
40 demyelinating disease 29.6 U2AF1 SERPINA3 PTPRC CCR6
41 chediak-higashi syndrome 29.5 SERPINA3 ITGAX CD207 CCR6
42 leiomyosarcoma 29.5 SERPINA3 S100B PTPRC PECAM1
43 central nervous system vasculitis 29.5 SERPINA3 IL1RN CCR6
44 adult xanthogranuloma 29.5 CD207 CD1C CD1A CD163
45 neurofibromatosis, type ii 29.2 SERPINA3 IL1RN CCR6
46 lung cancer susceptibility 3 29.2 U2AF1 SERPINA3 PECAM1 NRAS MAP2K1 CCR6
47 skin disease 29.1 TNFRSF8 SERPINA3 S100B CD1C CD1A CD163
48 mycobacterium tuberculosis 1 28.9 TNFRSF8 SERPINA3 PTPRC CD1C CD1A CCR6
49 dermatitis, atopic 28.9 TNFRSF8 SERPINA3 PTPRC ITGAX CCR6
50 spondyloarthropathy 1 28.9 IL1RN CD163 CCR6

Graphical network of the top 20 diseases related to Histiocytosis:



Diseases related to Histiocytosis

Symptoms & Phenotypes for Histiocytosis

Human phenotypes related to Histiocytosis:

31 (show all 7)
# Description HPO Frequency HPO Source Accession
1 osteolysis 31 hallmark (90%) HP:0002797
2 proptosis 31 hallmark (90%) HP:0000520
3 diabetes insipidus 31 hallmark (90%) HP:0000873
4 hepatomegaly 31 occasional (7.5%) HP:0002240
5 papule 31 occasional (7.5%) HP:0200034
6 pulmonary infiltrates 31 occasional (7.5%) HP:0002113
7 lymphadenopathy 31 occasional (7.5%) HP:0002716

MGI Mouse Phenotypes related to Histiocytosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.77 ARAF BRAF CCR6 CD101 CD163 CD207
2 immune system MP:0005387 9.44 ARAF BRAF CCR6 CD101 CD163 CD207

Drugs & Therapeutics for Histiocytosis

Drugs for Histiocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trametinib Approved Phase 4 871700-17-3 11707110
2
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
3 Protein Kinase Inhibitors Phase 4
4
Cytarabine Approved, Experimental, Investigational Phase 2, Phase 3 147-94-4, 65-46-3 6253
5
Cladribine Approved, Investigational Phase 2, Phase 3 4291-63-8 20279
6
Mercaptopurine Approved Phase 2, Phase 3 50-44-2 667490
7
Vinblastine Approved Phase 2, Phase 3 865-21-4 13342 241903
8
Indomethacin Approved, Investigational Phase 2, Phase 3 53-86-1 3715
9
Vincristine Approved, Investigational Phase 2, Phase 3 2068-78-2, 57-22-7 5978
10
Zoledronic Acid Approved Phase 3 118072-93-8 68740
11
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
12
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
13 Antiviral Agents Phase 2, Phase 3
14 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
15 Analgesics, Non-Narcotic Phase 2, Phase 3
16 Analgesics Phase 2, Phase 3
17 2-chloro-3'-deoxyadenosine Phase 2, Phase 3
18 Tocolytic Agents Phase 2, Phase 3
19 Cyclooxygenase Inhibitors Phase 2, Phase 3
20 Antimitotic Agents Phase 2, Phase 3
21 Immunoglobulins, Intravenous Phase 2, Phase 3
22 Rho(D) Immune Globulin Phase 2, Phase 3
23 gamma-Globulins Phase 2, Phase 3
24 Pharmaceutical Solutions Phase 3
25 Anesthetics Phase 3
26 Diphosphonates Phase 3
27 Immunologic Factors Phase 2, Phase 3
28 Immunosuppressive Agents Phase 2, Phase 3
29 Alkylating Agents Phase 2, Phase 3
30 Thymoglobulin Phase 2, Phase 3
31
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
32
Thioguanine Approved Phase 2 154-42-7 2723601
33
Etanercept Approved, Investigational Phase 2 185243-69-0
34
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
35
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
36 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
37
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
38
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
39
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
40
Iron Approved, Experimental Phase 2 7439-89-6, 15438-31-0 23925 27284
41
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
42
Dimethyl sulfoxide Approved, Vet_approved Phase 2 67-68-5 679
43
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
44
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
45
Olaparib Approved Phase 2 763113-22-0 23725625
46
Piperazine Approved, Vet_approved Phase 2 110-85-0 4837
47
Mebendazole Approved, Vet_approved Phase 2 31431-39-7 4030
48
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5005498 5330286
49
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
50
Denosumab Approved Phase 2 615258-40-7

Interventional clinical trials:

(show top 50) (show all 77)
# Name Status NCT ID Phase Drugs
1 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Not yet recruiting NCT03975829 Phase 4 dabrafenib;trametinib
2 H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis Completed NCT00488605 Phase 3 Prednisone, Vinblastin, 6-mercaptopuroine;Leucovorin, Methotrexate, Vinblastine, Prednisone
3 LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Recruiting NCT02205762 Phase 2, Phase 3 Prednisone;Vinblastine;mercaptopurine;INDOMETHACIN;Methotrexate;Cytosine Arabinoside;2-chlorodeoxyadenosine
4 Randomization of Cytarabine Monotherapy Versus Standard-of-Care Vinblastine/Prednisone for Frontline Treatment of Langerhans Cell Histiocytosis (TXCH LCH0115) Recruiting NCT02670707 Phase 3 Cytarabine;Vinblastine/prednisone
5 Cobimetinib for BRAF-wild-type Histiocytoses : a Randomized, Placebo-controlled, Double Blind Study" COBRAH Study Recruiting NCT04007848 Phase 3 Cobimetinib;Placebo oral tablet
6 Non-inferiority Trial of Three Cycles of Zoledronic Acid Versus Percutaneous Thermal Ablation in Osteoid Osteoma Recruiting NCT02739555 Phase 3 Acide Zoledronique MEDAC
7 In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders Terminated NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
8 The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells Unknown status NCT00084695 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
9 Transplantation Using Umbilical Cord And Placental Blood Unknown status NCT00008164 Phase 2
10 Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With Langerhans Cell in Histiocytosis (LCH) Completed NCT00588536 Phase 2 Methotrexate;6-Thioguanine;Leucovorin Calcium
11 Efficacy and Tolerance of Combination Chemotherapy With Methotrexate and Cytosine Arabinoside in Newly Diagnosed Adult With Langerhans Cell Histiocytosis Completed NCT02389400 Phase 2 methotrexate
12 A Phase 2a, Open Label, Multicenter Study to Assess the Efficacy and Safety of the Oral AKT Inhibitor GSK2110183 in Subjects With Langerhans Cell Histiocytosis Completed NCT01395004 Phase 2 GSK2110183
13 Treatment of Resistant Langerhans Cell Histiocytosis With Etanercept (ENBREL, IMMUNEX, SEATTLE) Completed NCT00048373 Phase 2 Etanercept
14 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
15 Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism Completed NCT00176865 Phase 2 Fludarabine;Melphalan;Anti-thymocyte globulin (ATG);Campath 1H;Cyclosporin A;Mycophenolate mofetil;Intravenous immunoglobulin (IVIG)
16 A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease Completed NCT02281760 Phase 2 Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide
17 HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies Completed NCT00145626 Phase 2 Chemotherapy and antibodies
18 CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease Completed NCT01049854 Phase 2 Full Intensity with TBI;Full Intensity;Reduced Intensity;Reduced Intensity (Fanconi)
19 Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation Completed NCT00055653 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;melphalan;methylprednisolone
20 Cytarabine Monotherapy for Adult Patients With Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study Recruiting NCT04121819 Phase 2 Cytarabine
21 Thalidomide, Cyclophosphamide and Dexamethasone for Adult Patients With Recurrent/Refractory Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study Recruiting NCT04120519 Phase 2 thalidomide combined with dexamethasone and cyclophosphamide
22 Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders Recruiting NCT02425904 Phase 2 Clofarabine
23 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes Recruiting NCT03233204 Phase 2 Olaparib
24 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes Recruiting NCT03526250 Phase 2 Palbociclib
25 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring Braf V600 Mutations Recruiting NCT03220035 Phase 2 Vemurafenib
26 Evaluation of Efficacy of Denosumab in Adult Patients With Langerhans Cell Histiocytosis (LCH): a Multiple-site, Single Arm, Open Label Clinical Trial Recruiting NCT03270020 Phase 2 Denosumab 70 MG/ML [Xgeva]
27 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions Recruiting NCT03213704 Phase 2 Larotrectinib;Larotrectinib Sulfate
28 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex Recruiting NCT03213665 Phase 2 Tazemetostat
29 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations Recruiting NCT03210714 Phase 2 Erdafitinib
30 NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of Ly3023414 in Patients With Solid Tumors Recruiting NCT03213678 Phase 2 Samotolisib
31 The Prospective Non-randomized Phase II Clinical Trial of Vemurafenib in Combination With Cytarabine and 2-chlorodeoxyadenosine in Children With Langerhans-cell Hisitocytosis With BRAF V600E Mutation Recruiting NCT03585686 Phase 2 Vemurafenib;Cytarabine;2-chlorodeoxyadenosine
32 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;Samotolisib;Selumetinib Sulfate;Tazemetostat;Ulixertinib;Vemurafenib
33 CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease Recruiting NCT02061800 Phase 1, Phase 2 Thiotepa;Cyclophosphamide;Alemtuzumab;Tacrolimus;Melphalan;Busulfan;Fludarabine;Methylprednisolone
34 Phase II Trial of Single-agent Cobimetinib for Adults With Histiocytic Disorders Recruiting NCT02649972 Phase 2 Cobimetinib
35 An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Children and Adolescents With Cancers Harboring V600 Mutations Recruiting NCT02124772 Phase 1, Phase 2 Trametinib;Dabrafenib
36 Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma Recruiting NCT01887522 Phase 2 Vinblastine + Nilotinib;Vinblastine
37 Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Patients With Pulmonary Langerhans Cell Histiocytosis and Impairment of Lung Function Active, not recruiting NCT01473797 Phase 2 Cladribine
38 A Phase II Study of Lenalidomide for Adult Histiocyte Disorders Active, not recruiting NCT02523040 Phase 2 Lenalidomide
39 Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment Active, not recruiting NCT03096782 Phase 2 Busulfan;Clofarabine;Cyclophosphamide;Fludarabine;Melphalan;Mycophenolate Mofetil;Tacrolimus
40 A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders. Not yet recruiting NCT04079179 Phase 2 Cobimetinib
41 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations Not yet recruiting NCT04195555 Phase 2 Ivosidenib
42 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations Suspended NCT03698994 Phase 2 Ulixertinib
43 Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis Terminated NCT00618540 Phase 2 fludarabine phosphate;melphalan
44 Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders Terminated NCT01050439 Phase 2
45 A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors Terminated NCT02012231 Phase 1, Phase 2 PLX8394
46 Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis Withdrawn NCT01796405 Phase 2 Clofarabine
47 PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA Unknown status NCT01884922 Phase 1 Nilotinib;Vinblastine
48 A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy Completed NCT00890747 Phase 1 sunitinib malate
49 Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies Completed NCT01471067 Phase 1 Melphalan;Fludarabine;Mycophenolate mofetil;Tacrolimus;Rituximab;ATG;Busulfan;Clofarabine
50 Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects With Advanced BRAF V600-Mutation Positive Solid Tumors Active, not recruiting NCT01677741 Phase 1 Dabrafenib

Search NIH Clinical Center for Histiocytosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Etoposide
etoposide phosphate
Thalidomide
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: histiocytosis

Genetic Tests for Histiocytosis

Anatomical Context for Histiocytosis

MalaCards organs/tissues related to Histiocytosis:

40
Bone, Lung, Lymph Node, Skin, Thyroid, T Cells, Liver

Publications for Histiocytosis

Articles related to Histiocytosis:

(show top 50) (show all 8741)
# Title Authors PMID Year
1
[Eosinophilic granuloma of the temporal bone. Case report and literature review]. 54 61
12717600 2003
2
Oral submucosal dendrocytes: factor XIIIa+ and CD34+ dendritic cell populations in normal tissue and fibrovascular lesions. 54 61
1282135 1992
3
Bone marrow imprints of crystal-storing histiocytosis. 61
31833659 2020
4
Altered cerebral perfusion in children with Langerhans cell histiocytosis after chemotherapy. 61
31802628 2020
5
Comment on: FDG PET-CT in pediatric Langerhans cell histiocytosis: Can all birds be killed with just one stone? 61
32037736 2020
6
Erdheim-Chester disease: expanding the spectrum of cutaneous manifestations. 61
31120137 2020
7
Radiation Therapy for Benign Disease: Arteriovenous Malformations, Desmoid Tumor, Dupuytren Contracture, Graves Ophthalmopathy, Gynecomastia, Heterotopic Ossification, Histiocytosis. 61
31739945 2020
8
Management of Hemophagocytic Lympho-Histiocytosis in Critically Ill Patients. 61
30384814 2020
9
Multiply relapsed mixed histiocytosis in an adult responding to clofarabine after failure of cladribine. 61
31483174 2020
10
Langerhans Cell Histiocytosis with Multiple Fluid-fluid Levels in the Parietal Bone. 61
30828044 2020
11
High levels of plasma interleukin-17A are associated with severe neurological sequelae in Langerhans cell histiocytosis. 61
31629106 2020
12
[Reaserch Advance on Langerhans Cell Histiocytosis Review]. 61
32027303 2020
13
Adult vulvar Langerhans cell histiocytosis: a rare presentation. 61
31605379 2020
14
Sonographic features of Rosai-Dorfman disease in the breast: A case report. 61
31638720 2020
15
Lung Involvement in Destombes-Rosai-Dorfman Disease: Clinical and Radiological Features and Response to the MEK Inhibitor Cobimetinib. 61
31669429 2020
16
Crystal-storing histiocytosis leading to the identification of IgG-kappa secreting lymphoplasmacytic lymphoma with crystalline nephropathy. 61
31883675 2020
17
[Langerhans cell histiocytosis revealed by a temporomandibular joint disorder: Report of a case and review of the craniofacial expressions]. 61
31474430 2020
18
Aggressive surgical management of recurrent intracranial juvenile xanthogranuloma: case report and review of the literature. 61
31385088 2020
19
Reticulohistiocytoses: a revision of the full spectrum. 61
31955466 2020
20
Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. 61
31004029 2020
21
Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. 61
31899802 2020
22
Clinical, histopathologic, and immunoarchitectural features of dermatopathic lymphadenopathy: an update. 61
31896812 2020
23
Mammary Extranodal Rosai-Dorfman Disease With and Without Associated Axillary Lymphadenopathy: Insights for Practitioners of Breast Pathology. 61
31992097 2020
24
Indeterminate cell histiocytosis in a patient with systemic lupus erythematosus and antiphospholipid antibody syndrome: an unusual association. 61
31789127 2020
25
Purpuric nail striae as the initial manifestation in multisystem Langerhans cell histiocytosis. 61
31697424 2020
26
Spectrum of 18F-FDG Uptake in Bilateral Lung Parenchymal Diseases on PET/CT. 61
31524673 2020
27
Diffuse Cystic Lung Diseases. 61
31615921 2020
28
Empirical treatment of massive lymphadenopathy in a child with mixed type histiocytosis in Kenya. 61
31908285 2020
29
Response to trametinib of histiocytosis with an activating PTPN11 mutation. 61
31393194 2020
30
Spinal epidural involvement in adult Langerhans cell histiocytosis (LCH): A case report. 61
32011480 2020
31
MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis. 61
31961828 2020
32
Cyclin D1 and BRAF V600E Immunohistochemical Staining in Pulmonary Langerhans Cell Histiocytosis. 61
31965621 2020
33
Teaching NeuroImages: CNS pituitary-hypothalamic Langerhans cell histiocytosis in an adult. 61
31932512 2020
34
Case of progression to multisystem Langerhans cell histiocytosis with polyostotic and cutaneous involvement from recurrent single-system monostotic Langerhans cell histiocytosis. 61
31677174 2020
35
Langerhans Cell Histiocytosis in an Adult: A Discussion of Epidemiology and Treatment Options. 61
31634312 2020
36
Solitary Bone Langerhans Cell Histiocytosis Demonstrated on Multimodality Imaging in an Adult. 61
31789916 2020
37
Circulating cell-free BRAFV600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis. 61
31919077 2020
38
Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis. 61
31758416 2020
39
The coming of age of Langerhans cell histiocytosis. 61
31831887 2020
40
Acquired Von Willebrand Syndrome Secondary to Langerhans Cell Histiocytosis. 61
31900848 2020
41
FDG PET-CT in pediatric Langerhans cell histiocytosis. 61
31599488 2020
42
A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria. 61
31940000 2020
43
Rosai-Dorfman disease manifesting as epibulbar and orbital tumor: A case report and literature review. 61
31914099 2020
44
Cytological Diagnosis of Rosai-Dorfman Disease: A Study of Twelve Cases with Emphasis on Diagnostic Challenges. 61
31942098 2020
45
Mutations in Receptor Tyrosine Kinases Drive Histiocytic Disorders. 61
31810984 2020
46
Post-scabietic nodules: Mimicker of infantile indeterminate cell histiocytosis and potential diagnostic pitfall. 61
31381175 2020
47
Craniocervical Rosai-Dorfman Disease Involving the Vertebral Artery: Case Report and Literature Review. 61
31550540 2020
48
Neuroimaging features of CNS histiocytosis syndromes. 61
31874337 2019
49
Cardiothoracic manifestations of Erdheim-Chester disease. 61
31386554 2019
50
Head and Neck Sinus Histiocytosis with Massive Lymphadenopathy Radiology-Pathology Correlation. 61
29855802 2019

Variations for Histiocytosis

Expression for Histiocytosis

Search GEO for disease gene expression data for Histiocytosis.

Pathways for Histiocytosis

Pathways related to Histiocytosis according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.45 TNFRSF8 SERPINA3 S100B PTPRC PECAM1 NRAS
2
Show member pathways
13.3 TNFRSF8 NRAS MAP2K1 ITGAX IL1RN BRAF
3
Show member pathways
12.74 NRAS MAP2K1 ITGAX BRAF ARAF
4 12.55 NRAS MAP2K1 ITGAX BRAF ARAF
5
Show member pathways
12.45 NRAS MAP2K1 BRAF ARAF
6
Show member pathways
12.36 NRAS MAP2K1 BRAF ARAF
7
Show member pathways
12.35 PTPRC NRAS MAP2K1 BRAF
8
Show member pathways
12.33 NRAS MAP2K1 ITGAX BRAF ARAF
9
Show member pathways
12.27 NRAS MAP2K1 BRAF ARAF
10 12.23 NRAS MAP2K1 BRAF ARAF
11
Show member pathways
12.22 NRAS MAP2K1 BRAF ARAF
12
Show member pathways
12.12 NRAS MAP2K1 BRAF ARAF
13
Show member pathways
12.12 NRAS MAP2K1 BRAF ARAF
14
Show member pathways
12.12 NRAS MAP2K1 ITGAX BRAF ARAF
15
Show member pathways
12.09 NRAS MAP2K1 BRAF ARAF
16
Show member pathways
12.06 NRAS MAP2K1 BRAF ARAF
17
Show member pathways
12 NRAS MAP2K1 BRAF ARAF
18
Show member pathways
11.98 NRAS MAP2K1 BRAF ARAF
19 11.88 PTPRC ITGAX CD1C CD163
20 11.86 NRAS MAP2K1 BRAF ARAF
21 11.83 NRAS MAP2K1 BRAF ARAF
22 11.82 MAP2K1 BRAF ARAF
23 11.8 NRAS MAP2K1 BRAF ARAF
24 11.72 PTPRC CD101 CCR6
25
Show member pathways
11.65 NRAS MAP2K1 BRAF ARAF
26 11.57 NRAS MAP2K1 BRAF ARAF
27 11.51 TNFRSF8 PTPRC CD1C
28
Show member pathways
11.48 NRAS MAP2K1 BRAF ARAF
29 11.45 MAP2K1 BRAF ARAF
30 11.4 NRAS MAP2K1 BRAF ARAF
31 11.22 NRAS MAP2K1 BRAF
32 11.19 NRAS MAP2K1 BRAF ARAF
33 11.04 NRAS MAP2K1 BRAF ARAF
34 10.97 PTPRC ITGAX CD207 CD1C CD1A CD163

GO Terms for Histiocytosis

Cellular components related to Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.86 TNFRSF8 STAB1 SLC29A3 PTPRC PECAM1 NRAS
2 external side of plasma membrane GO:0009897 9.17 PTPRC PECAM1 ITGAX CD1C CD1A CD163

Biological processes related to Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.77 SERPINA3 PTPRC PECAM1 NRAS ITGAX
2 MAPK cascade GO:0000165 9.71 NRAS MAP2K1 BRAF ARAF
3 regulation of axon regeneration GO:0048679 9.32 MAP2K1 BRAF
4 antigen processing and presentation, exogenous lipid antigen via MHC class Ib GO:0048007 9.26 CD1C CD1A
5 antigen processing and presentation, endogenous lipid antigen via MHC class Ib GO:0048006 9.16 CD1C CD1A
6 positive regulation of T cell mediated cytotoxicity GO:0001916 9.13 PTPRC CD1C CD1A
7 DN2 thymocyte differentiation GO:1904155 8.62 PTPRC CCR6

Molecular functions related to Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 U2AF1 TNFRSF8 STAB1 SLC29A3 SERPINA3 S100B
2 lipopeptide binding GO:0071723 9.26 CD1C CD1A
3 exogenous lipid antigen binding GO:0030884 8.96 CD1C CD1A
4 endogenous lipid antigen binding GO:0030883 8.62 CD1C CD1A

Sources for Histiocytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....